The stock of Cellectar Biosciences Inc (CLRB) has seen a 5.44% increase in the past week, with a -22.33% drop in the past month, and a -39.43% decrease in the past quarter. The volatility ratio for the week is 7.26%, and the volatility levels for the past 30 days are at 8.70% for CLRB. The simple moving average for the last 20 days is -6.80% for CLRB stock, with a simple moving average of -32.24% for the last 200 days.
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
The 36-month beta value for CLRB is at 0.99. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLRB is 34.69M, and currently, shorts hold a 8.19% of that float. The average trading volume for CLRB on August 15, 2024 was 625.29K shares.
CLRB) stock’s latest price update
Cellectar Biosciences Inc (NASDAQ: CLRB)’s stock price has increased by 1.75 compared to its previous closing price of 2.00. However, the company has seen a 5.44% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-13 that Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Jim Caruso – President and Chief Executive Officer Andrei Shustov – Senior Vice President-Medical Jarrod Longcor – Chief Operating Officer Shane Lea – Chief Commercial Officer Chad Kolean – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Jeff Jones – Oppenheimer Ted Tenthoff – Piper Sandler Operator Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today’s call is being recorded.
Analysts’ Opinion of CLRB
ROTH Capital, on the other hand, stated in their research note that they expect to see CLRB reach a price target of $10. The rating they have provided for CLRB stocks is “Buy” according to the report published on January 21st, 2020.
CLRB Trading at -19.89% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.27% of loss for the given period.
Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares sank -23.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.58% lower at present.
During the last 5 trading sessions, CLRB rose by +4.66%, which changed the moving average for the period of 200-days by -14.04% in comparison to the 20-day moving average, which settled at $2.15. In addition, Cellectar Biosciences Inc saw -26.53% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLRB
Current profitability levels for the company are sitting at:
- -127.91 for the present operating margin
- 0.19 for the gross margin
The net margin for Cellectar Biosciences Inc stands at -154.33. The total capital return value is set at -1.59. Equity return is now at value -304.38, with -176.58 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -70.31. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -340.69.
Currently, EBITDA for the company is -38.77 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of 99.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.54.
Conclusion
In conclusion, Cellectar Biosciences Inc (CLRB) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
